- $7.38m
- $12.72m
- $0.05m
Brief: HCW Biologics To Regain Full Rights For Two Commercial-Ready Reagents From Wugen
Brief: HCW Biologics Prices Private Placement Of 2.8 Mln Units At $1.405 Per Unit
NASDAQ RESUMED AT 09:59 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:54 AM
NASDAQ RESUMED AT 10:54 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:49 AM
NASDAQ RESUMED AT 10:18 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:13 AM
NASDAQ RESUMED AT 02:37 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:32 PM
NASDAQ RESUMED AT 10:28 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:23 AM
NASDAQ RESUMED AT 09:38 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM
HCW Biologics Q1 revenue surges on licensing deal
Brief: HCW Biologics Discovers That HCW11-040 Prevents Bronchopulmonary Dysplasia During IND-Enabling Studies
Brief: Hcw Biologics Delivers A Major Update For Its T-Cell Engager Program Revealing Mechanism Of Action
HCW Biologics Q4 revenue drops sharply on license suspension
Brief: Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic